Jason Fontenot, PhD

Chief Scientific Officer

Jason Fontenot is Immusoft’s Chief Scientific Officer.  He has more than 20 years of experience in life sciences research and drug development.

He is an internationally recognized immunologist with extensive expertise in immune cell biology, cell engineering and immune-mediated disease. Jason’s seminal work with Dr. Alexander Rudensky on regulatory T cells and the transcription factor, FOXP3, transformed the study of immune regulation and produced some of the most highly cited publications in the field of immunology in the last 20 years.

Before joining Immusoft, Jason was the Head of Exploratory Research at Juno Therapeutics, responsible for advancing the company’s early stage engineered T cell therapy pipeline. In his role at Juno, he oversaw the development of next generation cellular and genetic engineering strategies in collaboration with internal and external partners and managed major research partnerships with leading biotech and academic institutions including Editas Medicine, Fate Therapeutics and UCSF.

Prior to Juno Therapeutics, Jason worked at Biogen in Cambridge Mass., where his team focused on T cell biology and immune regulation. In addition to leading multiple exploratory stage research programs, Jason worked on several major drug development programs at Biogen including the TecfideraÔand TysabriÔ. He served as preclinical program team lead on the ZinbrytaÔprogram in Multiple Sclerosis from early clinical development to FDA approval.

Jason received his B.S. degree from Louisiana State University and his Ph.D. from the Immunology Department at the University of Washington in Seattle.